CR-CP Life Science Fund

Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.

NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.

Mirxes is a biotechnology company that discovers, develops, and delivers accurate preventive healthcare solutions for cancer, cardiovascular, metabolic and infectious diseases. The company's mission is to make diagnostic solutions for the early detection of diseases accessible on a global scale. It develops and commercializes accurate and non-invasive blood-based miRNA test kit products for the early detection of cancer and other diseases.

Mirxes is a biotechnology company that discovers, develops, and delivers accurate preventive healthcare solutions for cancer, cardiovascular, metabolic and infectious diseases. The company's mission is to make diagnostic solutions for the early detection of diseases accessible on a global scale. It develops and commercializes accurate and non-invasive blood-based miRNA test kit products for the early detection of cancer and other diseases.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.

BELKIN Vision focuses on developing a laser device that aids healthcare professionals in the treatment of glaucoma. The company's technology offers a non-invasive, non-contact, instantaneous, painless, and automated approach to laser therapy. By promoting accessibility to first-line drop-less glaucoma care, BELKIN Vision enables any ophthalmologist to effectively treat patients. This innovation aims to enhance treatment outcomes and improve the overall quality of care for individuals suffering from glaucoma.

New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Genor BioPharma Co., Ltd. is a biopharmaceutical company based in Shanghai, China, founded in 2007. It specializes in the development and commercialization of therapeutic monoclonal antibodies (mAbs) and Fc-fusion protein drugs, focusing primarily on oncology, autoimmune diseases, and metabolic disorders. The company aims to address significant unmet medical needs through its pipeline, which includes more than ten products, with several already in clinical development. Notable candidates include GB491, an oral CDK4/6 inhibitor; GB221, a novel HER2 mAb; geptanolimab (GB226); and GB242, an infliximab biosimilar. Genor BioPharma also collaborates strategically with Ascentage Pharma to enhance its research and development efforts.

Transcenta Holding Ltd. is a clinical-stage biotherapeutics company focused on the research, development, and manufacturing of antibody-based therapeutics. Established in 2019 and headquartered in Suzhou, China, the company operates additional facilities in Shanghai, Hangzhou, Beijing, Waltham, and Princeton. Transcenta's integrated approach encompasses the discovery and development of innovative antibodies aimed at addressing various medical conditions, particularly in oncology and specific non-oncology areas such as bone and kidney disorders. The company is currently advancing nine therapeutic antibody molecules through clinical development, underscoring its commitment to improving patient outcomes. Transcenta was formed through the merger of HJB and MabSpace Biosciences, positioning it as a significant player in the global biopharmaceutical landscape.

CF PharmTech, Inc. is a specialty pharmaceutical company based in Suzhou, China, focused on the development and manufacturing of inhalation products for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. Founded in 2007, the company offers a range of products including metered dose inhalers, dry powder inhalers, nasal sprays, and nebulizers. In addition to its product offerings, CF PharmTech provides contract manufacturing organization (CMO) services and is actively involved in research and development in its specialized field. The company aims to provide high-quality and affordable medicines to enhance patient care and management of respiratory conditions, catering to a global market. Its headquarters are strategically located in the Caohu District, ensuring convenient transportation access to major cities like Shanghai and Beijing.

Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.